ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
ASH Update on CML Management: Does the TKI Choice Affect Survival? Are There Any Superiorities Between Dasatinib & Nilotinib? What Is Efficacy/Safety, and MMR Rate of a First-in-Class Stamp Inhibitor vs. Bosutinib?
Comments 0
Login to view comments.
Click here to Login
